Skip to content
  • IFPMA Twitter
  • IFPMA LinkedIn
  • IFPMA Youtube
  • IFPMA Slideshare
  • IFPMA Flickr
  • IFPMA RSS
IFPMA
  • Who We Are
    • IFPMA in Brief
    • Our Governance and Leadership
    • Our Membership
      • Full Members
        • Associations
        • Companies
      • Affiliate Members
    • Our Experts
    • Join Us
  • Topics
  • News Center
    • News Releases
    • Blog
      • Global Health Matters
      • Science Matters
      • DG’s Column
    • Statements
  • Resources
    • Publications
      • News Releases
      • Statements
      • Position Papers
      • Publications
      • External Studies
      • Infographics
      • Event Highlights
    • Multimedia
      • Interviews
      • Videos
      • Slides
    • IFPMA Interactive Platforms
      • IFPMA COVID-19 Hub
      • Global Health Progress
      • 50 Years of Global Health Progress
  • Events
    • Upcoming IFPMA Events
      • Geneva Pharma Forums
      • Assemblies
      • Other IFPMA Events
      • IFPMA in External Events
      • IFPMA Press Briefings
    • Past IFPMA Events
      • Geneva Pharma Forums
      • Assemblies
      • Other IFPMA Events
      • IFPMA in External Events
      • IFPMA Press Briefings
  • Partners
  • BCR
  • Inventing Medicines and Vaccines
  • Strengthening Regulatory Systems
  • Ethics and Business Integrity
  • Boosting Innovation and Access
  • Tackling Global health challenges
Climate change Economic footprint IP Sustainable innovation Value of innovation

spotlight

Value of innovation

Inventing Medicines and Vaccines
African Medicines Agency Biosimilars Biotherapeutic medicines Falsified medicines Import testing Pharmacovigilance Quality, safety, and efficacy Regulatory conferences Regulatory system strengthening / Harmonization Supply chain The Africa Regulatory Network (ARN) The ARN: Le réseau africain de réglementation pharmaceutique

spotlight

Pharmacovigilance

Strengthening Regulatory Systems
IFPMA Code of Practice (2019) Our Ethos in Action Our Ethos Code eLearning Tool IFPMA Notes for Guidance IFPMA Complaint Operating Procedure How to File a Code Complaint Complaint Submission Form Cases Business Ethics for APEC SMEs Initiative Consensus Framework for Ethical Collaboration

spotlight

IFPMA Code of Practice (2019)

Ethics and Business Integrity
Access to medicines Global Policy Principles on Digital Health Health technology assessment IP Technology Transfer Trade

spotlight

Access to medicines

Boosting Innovation and Access
Ageing Antimicrobial resistance Cancer Child and maternal health COVID-19 Diabetes Ebola Falsified medicines HIV/AIDS Influenza Malaria Mental and neurological disorders Neglected tropical diseases Non-communicable diseases Pandemic Preparedness Public health implications of the implementation of the Nagoya Protocol Rare diseases Supply chain Sustainable development goals Tuberculosis Universal Health Coverage Vaccination confidence Vaccines innovation Vaccines protect communities Vaccines sustainability Value of immunization Viral hepatitis

spotlight

Universal Health Coverage

Tackling Global health challenges
  • Home
  • >
  • Resources
  • >
  • Publications
  • >
  • Ethical Considerations for Resuming In-Person Interactions with Healthcare Professionals Post COVID-19: A Guidance Document

Ethical Considerations for Resuming In-Person Interactions with Healthcare Professionals Post COVID-19: A Guidance Document

Published on: 28 May 2020

Downloads

» IFPMA_Ethical_Considerations_F2F_Interactions

Resources

IFPMA President David Ricks on Global Pledge Committing to Work Together to Beat COVID-19 (Video)
Videos

Videos

IFPMA President David Ricks on Global Pledge Committing to Work Together to Beat COVID-19 (Video)

The value of the Ethos in the context of COVID-19
Videos

Videos

The value of the Ethos in the context of COVID-19

IFPMA Code of Practice 2019
Publications

Publications

IFPMA Code of Practice 2019

IFPMA Code of Practice 2019 – Our Ethos
Publications

Publications

IFPMA Code of Practice 2019 – Our Ethos

COVID-19 Biopharmaceutical Industry – Regulatory Guiding Principles (May 2020)
Publications

Publications

COVID-19 Biopharmaceutical Industry – Regulatory Guiding Principles (May 2020)

Global Biopharmaceutical Industry Commitment to Address Coronavirus Public Health Crisis
Statements

Statements

Global Biopharmaceutical Industry Commitment to Address Coronavirus Public Health Crisis

Related Blog Entries

Five Questions to …. David King

Five Questions to …. David King

Ethical business stimulates best value in health economy

Ethical business stimulates best value in health economy

Cultivating Trust in Healthcare System

Cultivating Trust in Healthcare System

Related Links

IFPMA COVID-19 Innovation Timeline

Related Topics

Our Ethos
COVID-19
IFPMA Code of Practice (2019)

Tags

  • Code of Practice
  • Compliance
  • Epidemics
  • Ethics
  • ethos
  • global health security
  • Healthcare Professionals
  • Novel Coronavirus (COVID-19)
  • pandemics
  • Trust
IFPMA

Chemin des Mines 9
1202 Geneva
Switzerland

+41 22 338 32 00
info@ifpma.org

  • File a Code Complaint
  • Privacy Policy
  • Terms of Use
  • Access to Our Extranet
  • Careers
  • Contact Us
  • IFPMA Twitter
  • IFPMA LinkedIn
  • IFPMA Youtube
  • IFPMA Slideshare
  • IFPMA Flickr
  • IFPMA RSS
Designed and Produced by ACW
^ Back to Top